Omzo vs He & She MD: Compounded GLP-1, Price and Support Compared
Quick verdict: For lower introductory monthly pricing and built-in coaching choose He & She MD; for clinician-guided compounded programs with explicit compounded-medication disclosures choose Omzo.
Omzo vs He & She MD both sell compounded GLP-1 options, but they differ on pricing structure, bundled coaching, medication formats, and regulatory disclosures. This comparison lays out the most distinctive differences so you can pick based on price model, support, medication options, and regulatory notes.
See Omzo clinician-guided plans
Pricing model and introductory rates
Omzo lists a starting price of $179 for personalized compounded semaglutide and a starting tirzepatide price of $279, presented as clinician-guided fees. He & She MD advertises semaglutide from $139/month and tirzepatide from $199/month as six-month introductory rates that renew higher after that term. The key difference is Omzo shows starting single prices, while He & She MD structures six-month intro pricing that renews at a higher six-month rate.
Check He & She MD intro pricing
Bundled coaching and clinician access
He & She MD bundles a coaching app with 1:1 clinician messaging and GLP-1-specific tracking at no extra cost, positioning support and accountability as part of the plan. Omzo emphasizes clinician-guided plans reviewed by licensed U.S. providers but does not present a built-in coaching app as part of the captured evidence.
Explore Omzo clinician review process
Medication formats and fulfillment
Both providers offer compounded semaglutide and tirzepatide options. He & She MD lists three formats: semaglutide injection, oral semaglutide, and tirzepatide injection. Omzo highlights compounded semaglutide and tirzepatide, one weekly injection, and notes that providers may alternatively write prescriptions for branded FDA-approved medications which the company does not sell or ship.
Regulatory and safety disclosures
Both sources state that their compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Omzo specifically notes its compounded drugs are prepared by a state-licensed sterile compounding pharmacy and are produced in FDA-registered facilities but are not FDA-approved. He & She MD states its medications are produced in USP-compliant, state-regulated pharmacies but not reviewed by the FDA.
Renewal, shipping and extra fees
He & She MD includes free expedited shipping and no membership fee in its offering and warns that headline prices are six-month intro rates that renew 30-45% higher. Omzo mentions fast, discreet delivery and FSA & HSA eligibility in captured bullets, while advising customers to confirm eligibility, total cost, renewal terms and state availability before enrollment.
| Criteria | Omzo | He & She MD |
|---|---|---|
| Starting price | $179 for semaglutide; $279 for tirzepatide | $139/mo intro semaglutide; $199/mo intro tirzepatide |
| Price structure | Clinician-guided starting fees | Six-month introductory rates that renew higher |
| Coaching and clinician access | Clinician-guided plans reviewed by licensed U.S. providers | App with 1:1 clinician messaging, coaching and tracking included |
| Medication formats | Compounded semaglutide and tirzepatide, one weekly injection; branded prescriptions possible | Semaglutide injection, oral semaglutide, tirzepatide injection |
| Regulatory note | Compounded meds not FDA-approved; produced in FDA-registered facilities | Compounded meds not reviewed by FDA; produced in USP-compliant, state-regulated pharmacies |
| Shipping | Fast, discreet delivery; FSA & HSA eligible | Free expedited shipping; no membership fee |
Comparison highlights
- Choose He & She MD if you prioritize lower introductory monthly pricing and built-in coaching with 1:1 clinician messaging and progress tracking.
- Choose Omzo if you want clinician-guided compounded programs described with single starting fees and explicit notes about provider discretion to prescribe branded medications instead.
- Both providers note compounded GLP-1 medications are not FDA-approved and recommend confirming eligibility and terms before enrollment.
Both services require clinician consultation and state availability checks; neither guarantees outcomes and both preserve qualifiers about compounded medications and provider discretion.
Final recommendation
Omzo vs He & She MD comes down to price model and program support. He & She MD is better for people who want bundled coaching, 1:1 clinician messaging and an introductory monthly price for a six-month term. Omzo is better for people who prefer clinician-guided compounded plans presented as starting fees and who want the option that providers may prescribe branded medications to fill separately.
Choose He & She MD if you want coaching and app-based clinician access with a lower six-month introductory price. Choose Omzo if you want clinician-guided compounded semaglutide or tirzepatide with explicit compounded-medication disclosures and single starting fees. For both, confirm eligibility, renewal terms and state availability before enrollment.